Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC
Status:
Completed
Trial end date:
2023-08-08
Target enrollment:
Participant gender:
Summary
This clinical study was a first-in-human, phase 1B, single-center, single-arm, open-label,
dose escalation and expansion trial that aimed to determine the safety, tolerability and
efficacy of BEBT-109 in patients with locally advanced or metastatic NSCLC harboring EGFR
exon20ins mutations who had received at least one line of previous treatment.